このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Bicycle Therapeutics 将来の成長
Future 基準チェック /26
Bicycle Therapeutics利益と収益がそれぞれ年間0.7%と50.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-47.2% 10.3%なると予測されています。
主要情報
5.4%
収益成長率
13.8%
EPS成長率
| Biotechs 収益成長 | 28.3% |
| 収益成長率 | 52.2% |
| 将来の株主資本利益率 | -47.2% |
| アナリストカバレッジ | Good |
| 最終更新日 | 19 Sep 2024 |
今後の成長に関する最新情報
Recent updates
Bicycle Therapeutics Is Looking Increasingly Attractive
Aug 20Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert
May 24Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why
May 10
Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher
May 04Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?
Apr 19Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
Mar 12Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely
Jan 04Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts
Nov 07The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts
May 14Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%
Mar 31Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?
Mar 09Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook
Nov 08Bicycle Therapeutics: Exploring An Intriguing Developmental Platform
Oct 08Bicycle Therapeutics initiated Outperform at Cowen citing drug platform
Aug 31Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration
Jul 12Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?
Jul 10Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer
Jul 05Bicycle Therapeutics: Trying To Catch This Falling Knife
Apr 17Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Apr 11Bicycle Therapeutics: A Buy Ahead Of AACR Presentation
Mar 25Bicycle Therapeutics: An Oncology Play With Big Potential
Feb 28Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?
Nov 07Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
Aug 25The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically
Aug 07News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts
May 08Bicycle Therapeutics EPS misses by $0.05, beats on revenue
May 06業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2026 | 63 | -268 | -218 | -159 | 10 |
| 12/31/2025 | 35 | -236 | -208 | -169 | 12 |
| 12/31/2024 | 42 | -179 | -139 | -104 | 12 |
| 6/30/2024 | 40 | -165 | -165 | -164 | N/A |
| 3/31/2024 | 42 | -168 | -86 | -85 | N/A |
| 12/31/2023 | 27 | -181 | -64 | -61 | N/A |
| 9/30/2023 | 25 | -162 | -48 | -44 | N/A |
| 6/30/2023 | 23 | -140 | -55 | -48 | N/A |
| 3/31/2023 | 15 | -124 | -122 | -106 | N/A |
| 12/31/2022 | 14 | -113 | -105 | -86 | N/A |
| 9/30/2022 | 15 | -101 | -85 | -66 | N/A |
| 6/30/2022 | 16 | -87 | -54 | -39 | N/A |
| 3/31/2022 | 14 | -78 | -34 | -27 | N/A |
| 12/31/2021 | 12 | -67 | -17 | -15 | N/A |
| 9/30/2021 | 12 | -66 | -22 | -21 | N/A |
| 6/30/2021 | 11 | -62 | -54 | -53 | N/A |
| 3/31/2021 | 11 | -56 | -54 | -53 | N/A |
| 12/31/2020 | 10 | -51 | -19 | -18 | N/A |
| 9/30/2020 | 12 | -38 | -7 | -6 | N/A |
| 6/30/2020 | 9 | -37 | -8 | -7 | N/A |
| 3/31/2020 | 9 | -35 | -4 | -2 | N/A |
| 12/31/2019 | 14 | -31 | -30 | -29 | N/A |
| 9/30/2019 | 10 | -33 | -34 | -33 | N/A |
| 6/30/2019 | 11 | -31 | -28 | -26 | N/A |
| 3/31/2019 | 11 | -26 | -25 | -24 | N/A |
| 12/31/2018 | 7 | -22 | -27 | -26 | N/A |
| 9/30/2018 | 7 | -21 | -20 | -19 | N/A |
| 12/31/2017 | 2 | -16 | N/A | -1 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: BCYC今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: BCYC今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: BCYC今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: BCYCの収益 ( 47.1% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。
高い収益成長: BCYCの収益 ( 47.1% ) 20%よりも速いペースで成長すると予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: BCYC 3 年以内に赤字になると予測されています。